#1 Clinical Trials Search in Europe

Daunorubicin

Daunorubicin is an important chemotherapy drug being studied in clinical trials for the treatment of acute myeloid leukemia (AML). These trials are exploring how daunorubicin can be combined with other drugs or used in new formulations to improve outcomes for AML patients, especially older adults who often have poorer prognoses. The research aims to find more effective and safer ways to use daunorubicin in treating this aggressive blood cancer.

Table of Contents

What is Daunorubicin?

Daunorubicin is a powerful chemotherapy drug used primarily in the treatment of various types of leukemia. It belongs to a class of medications called anthracyclines, which are known for their ability to interfere with cancer cell growth[1]. This drug is also known by several other names, including:

  • Daunomycin
  • Rubidomycin
  • Cerubidine (when in the form of daunorubicin hydrochloride)
  • DNR (an abbreviation commonly used by healthcare professionals)

Daunorubicin comes in different formulations, including a standard form and a liposomal form called DaunoXome. The liposomal form is a special preparation where the drug is encased in tiny fat bubbles, which can help deliver the medication more effectively to cancer cells[1][2].

How Daunorubicin Works

Daunorubicin works by interfering with the DNA in cancer cells. Specifically, it inserts itself into the DNA structure, preventing the cells from making copies of themselves. This action stops cancer cells from growing and dividing, ultimately leading to their death[3]. By targeting rapidly dividing cells, daunorubicin is particularly effective against fast-growing cancers like leukemia.

Conditions Treated with Daunorubicin

Daunorubicin is primarily used to treat several types of cancer, including:

  • Acute Myeloid Leukemia (AML): This is the most common condition treated with daunorubicin. AML is a type of cancer that affects the blood and bone marrow[1][4].
  • Acute Lymphocytic Leukemia (ALL): Another type of blood cancer that daunorubicin can be used to treat[5].
  • Kaposi’s Sarcoma: In its liposomal form (DaunoXome), daunorubicin can be used to treat Kaposi’s sarcoma in patients with HIV[2].

How Daunorubicin is Administered

Daunorubicin is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosage and schedule can vary depending on the specific condition being treated, the patient’s overall health, and other factors. Some common administration schedules include:

  • Given on days 1-3 of a treatment cycle[3]
  • Given on days 1 and 3 of a treatment cycle[4]
  • In some cases, it may be given as a continuous infusion over several days[2]

Your healthcare team will determine the best schedule for your specific situation.

Daunorubicin in Combination Therapy

Daunorubicin is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

  • Daunorubicin + Cytarabine: This combination, often referred to as the “3+7” regimen, is a standard treatment for AML. Daunorubicin is given for 3 days, while cytarabine is given for 7 days[1].
  • Daunorubicin + Cytarabine + Venetoclax: This three-drug combination is being studied in clinical trials for newly diagnosed AML patients[6].
  • Liposomal Daunorubicin + Cytarabine: This combination, known as CPX-351 or Vyxeos, is used in certain types of AML[4].

Current Clinical Trials

Several ongoing clinical trials are exploring new ways to use daunorubicin or improve its effectiveness:

  • A study comparing standard daunorubicin to liposomal daunorubicin (DaunoXome) in elderly AML patients[1].
  • Research on the combination of daunorubicin, cytarabine, and venetoclax in newly diagnosed AML patients[6].
  • A trial studying low-dose daunorubicin in relapsed or refractory acute leukemia[5].

Potential Side Effects

Like all chemotherapy drugs, daunorubicin can cause side effects. Some potential side effects include:

  • Lowered blood cell counts, which can increase the risk of infection, anemia, and bleeding
  • Nausea and vomiting
  • Hair loss
  • Mouth sores
  • Fatigue
  • Heart problems (in some cases, especially with high doses)

It’s important to discuss potential side effects with your healthcare team. They can provide strategies to manage these effects and monitor your health closely during treatment[7].

Aspect Details
Main Focus Daunorubicin in clinical trials for Acute Myeloid Leukemia (AML)
Key Combinations Daunorubicin + Cytarabine, Liposomal Daunorubicin, Daunorubicin + Venetoclax
Patient Groups Newly diagnosed AML, Elderly AML patients, Relapsed/Refractory AML
Administration Intravenous (IV), often in cycles with other drugs
Outcome Measures Complete Remission rates, Overall Survival, Minimal Residual Disease, Safety/Toxicity
Novel Approaches Liposomal formulations, Low-dose regimens, Combination with targeted therapies

FAQ

  • What is daunorubicin and how does it work? Daunorubicin is a chemotherapy drug called an anthracycline. It works by damaging the DNA in cancer cells, which prevents them from growing and dividing. This helps kill leukemia cells in the body.
  • Why is daunorubicin being studied in new ways for AML? While daunorubicin is already used to treat AML, researchers are studying new combinations and formulations to try to improve its effectiveness and reduce side effects, especially for older patients who often have worse outcomes with standard treatments.
  • What is liposomal daunorubicin? Liposomal daunorubicin (like DaunoXome) is a special formulation where the drug is enclosed in tiny fat bubbles called liposomes. This may allow the drug to work better with fewer side effects compared to standard daunorubicin.
  • How is daunorubicin typically given in these trials? In most trials, daunorubicin is given intravenously (through an IV) over several days, often combined with other chemotherapy drugs like cytarabine. The exact schedule varies between studies.
  • What are some of the potential side effects of daunorubicin? Common side effects can include lowered blood cell counts (which can increase risk of infection, bleeding, or fatigue), nausea, hair loss, and mouth sores. It can also potentially cause heart problems, so heart function is closely monitored during treatment.

Ongoing Clinical Trials on Daunorubicin

  • Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Finland The Netherlands Norway Spain +1

  • Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

    Recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Study of Cytarabine, Daunorubicin, and Clofarabine for Children with Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Denmark Germany Italy The Netherlands Spain

  • Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland Germany +8

  • Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Estonia Finland Germany Lithuania +2

  • Study Comparing CPX-351 and Chemotherapy for Patients with New Intermediate or High-Risk Acute Myeloid Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Germany Greece Italy Poland

  • Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +13

  • Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Germany Italy The Netherlands +1

Glossary

  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, causing rapid growth of abnormal white blood cells.
  • Anthracycline: A class of chemotherapy drugs, including daunorubicin, that work by damaging cancer cell DNA.
  • Complete Remission (CR): A treatment response where there are no detectable cancer cells and blood counts have returned to normal.
  • Cytarabine: A chemotherapy drug often used in combination with daunorubicin to treat AML.
  • Induction Therapy: The first phase of leukemia treatment, aimed at achieving remission by killing as many cancer cells as possible.
  • Liposomal: A drug delivery method where the medication is enclosed in tiny fat bubbles to potentially improve its effectiveness and reduce side effects.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain after treatment, often detectable only by very sensitive tests.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Venetoclax: A targeted therapy drug that is being studied in combination with daunorubicin and other chemotherapies for AML treatment.

References

  1. https://clinicaltrials.gov/study/NCT00589082
  2. https://clinicaltrials.gov/study/NCT00427414
  3. https://clinicaltrials.gov/study/NCT00840684
  4. https://clinicaltrials.gov/study/NCT05801835
  5. https://clinicaltrials.gov/study/NCT02914977
  6. https://clinicaltrials.gov/study/NCT06697327
  7. https://clinicaltrials.gov/study/NCT03724084